Erratum: Management of fat accumulation in patients with HIV infection (Current HIV/AIDS Reports (2011) 8 (200-208)DOI 10.1007/s11904-011-0087-3);Management of fat accumulation in patients with HIV infection

Current HIV/AIDS Reports

Volumn 8, Issue 3, 2011, Pages 200-208

  Falutz, Julian ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Adipocyte; Aging; Ggrowth hormone; Growth hormone deficiency; Growth hormone releasing factor; HIV; Immune recovery; Inflammation; Lipoatrophy; Lipohypertrophy; Mitochondria; Obesity; Visceral adipose tissue

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; PLACEBO; RALTEGRAVIR; RECOMBINANT GROWTH HORMONE; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERMORELIN; STAVUDINE; TESAMORELIN; ZIDOVUDINE;

ABDOMINAL OBESITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAABDOMINAL FAT; LIPID STORAGE; LIPIDOSIS; LIPOATROPHY; LIPODYSTROPHY; MORTALITY; MUSCULOSKELETAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; QUALITY OF LIFE; SIDE EFFECT; SINGLE DRUG DOSE; VIRUS REPLICATION; WAIST CIRCUMFERENCE;

EID: 80055037960     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-011-0097-1     Document Type: Erratum

References (73)

1. Hogg R, Lima V, Sterne J, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9.
2. Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787-94.
3. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-55.
4. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010;24:1877-86.
5. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non- AIDS diseases following initial treatment for HIV infection. AIDS 2008;22:841-8. (Pubitemid 351563833)
6. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51:435-47.
7. Heaton RK, Clifford DB, Franklin Jr DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-96.
8. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-46.
9. Falutz J. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies. Curr Opin Clin Nutr Metab Care. 2011. doi:10.1097/MCO.0b013e3283457a8f.
10. Scherzer R, Heymsfield S, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all- 206 cause mortality in HIV infection. Abstract No.76. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February, 2011.
11. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:228-37. (Pubitemid 29156959)
12. Decrion AZ, Dichamp I, Varin A, et al. HIV and inflammation. Curr HIV Res. 2005;3:243-59. (Pubitemid 41052424)
13. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009;23:1059-67.
14. Schaffler A, Muller-Ladner U, Scholmerich J, et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev. 2006;27:449-67. (Pubitemid 44213227)
15. Giles JT, Allison M, Blumenthal RS, et al. Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum. 2010;62:3173-82.
16. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8. (Pubitemid 28190689)
17. Mallon PW, Wand H, Law M, et al. Buffalo hump seen in HIVassociated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J Acquir Immune Defic Syndr. 2005;38:156-62. (Pubitemid 40189322)
18. He Q, Engelson ES, Ionescu G, et al. Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men. Antivir Ther. 2008;13:423-8. (Pubitemid 352016735)
19. Lo J, Abbara S, Rocha-Filho JA, et al. Increased epicardial adipose tissue volume in HIV-infected men and relationships to body composition and metabolic parameters. AIDS 2010;24:2127-30.
20. Grunfeld C, Rimland D, Gibert CL, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr. 2007;46:283-90. (Pubitemid 350287354)
21. Albu JB, Kenya S, He Q, et al. Independent associations of insulin resistance with high whole-body intermuscular and low leg subcutaneous adipose tissue distribution in obese HIV-infected women. Am J Clin Nutr. 2007;86:100-6. (Pubitemid 47041598)
22. Torriani M, Thomas BJ, Barlow RB, et al. Increased intramyocellular lipid accumulation in HIV-infected women with fat redistribution. J Appl Physiol. 2006;100:609-14. (Pubitemid 43671615)
23. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-31. (Pubitemid 41395709)
24. Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30:1647-52.
25. Plank LD. Dual-energy X-ray absorptiometry and body composition. Curr Opin Clin Nutr Metab Care. 2005;8:305-9. (Pubitemid 40586190)
26. Park YW, Heymsfield SB, Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes Relat Metab Disord. 2002;26:978-83. (Pubitemid 34756182)
27. Krakauer JC, Franklin B, Kleerekoper M, et al. Body composition profiles derived from dual-energy X-ray absorptiometry, total body scan, and mortality. Prev Cardiol. 2004;7:109-15.
28. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes. 2004;53:2087-94. (Pubitemid 38970759)
29. Marques MD, Santos RD, Parga JR, et al. Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis. 2010;209:481-6.
30. Garrabou G, Lopez S, Moren C, et al. Mitochondrial damage in adipose tissue of untreated HIV-infected patients. AIDS 2011;25:165-70.
31. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion. 2004;4:763-77. (Pubitemid 39646821)
32. Kim MJ, Leclercq P, Lanoy E, et al. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIVinfected patients: the ANRS EP29 Lipostop Study. Antivir Ther. 2007;12:1273-83.
33. Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol. 2009;37:65-77.
34. Blas-Garcia A, Apostolova N, Ballesteros D, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology. 2010;52:115-25.
35. El Hadri K, Glorian M, Monsempes C, et al. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3 T3 and human preadipocytes or adipocytes. J Biol Chem. 2004;279:15130-41. (Pubitemid 38618908)
36. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109-18.
37. Boothby M, McGee KC, Tomlinson JW, et al. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14:1089-100.
38. McComsey G, Kitch D, Sax P, et al. Central fat accumulation in ART-naive subjects randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, A substudy of ACTG A5202. Abstract 77. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 27 - March 2, 2011.
39. Poizot-Martin I, Obry-Roguet V, Biron C, et al. Abdominal adiposity remains highly prevalent in French HIV-infected patients having initiated antiretroviral therapy after 2005. Abstract PS11/1. Presented at the 12th European AIDS Conference/EACS. Cologne, Germany. November 11-14, 2009.
40. Carr A, Ritzhaupt A, Zhang W, et al. Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS 2008;22:2313-21.
41. Moyle G, Hu W, Yang R, et al. Body Composition Changes in Treatment-Naive Patients Treated with Boosted Protease Inhibitors Plus Tenofovir/Emtricitabine: Results from the CASTLE Study Through 96 Weeks. Presented at the 12th European AIDS Conference/EACS. Cologne, Germany. November 11-14, 2009.
42. Jemsek JG, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis. 2006;42:273-80. (Pubitemid 43054203)
43. McComsey G, Rightmire A, Wirtz V, et al. Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study. Clin Infect Dis. 2009;48:1323-6.
44. Caron-Debarle M, Lagathu C, Boccara F, et al. HIV-associated lipodystrophy: from fat injury to premature aging. Trends in Molecular Medicine. 2010;16:218-29.
45. Rockstroh J, Lennox J, DeJesus A, et al. Raltegravir (RAL) demonstrates durable virologic suppression and superior immunologic response with a favorable metabolic profile through 3 years of treatment (Tx): 156 week (Wk) results from STARTMRK. Abstract 542. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 27-March 2, 2011.
46. Jacobson DL, Knox T, Spiegelman D, et al. Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. Clin Infect Dis. 2005;40:1837-45. (Pubitemid 40799956)
47. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr. 2003;34:58-61. (Pubitemid 37100112)
48. Zanone Poma B, Riva A, Nasi M, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 2008;22:1769-78.
49. Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One. 2010;5:e10106.
50. Wunder DM, Bersinger NA, Fux CA, et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther. 2007;12:261-5. (Pubitemid 46569911)
51. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.
52. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010;170:1135-41.
53. Kayaniyil S, Vieth R, Harris SB, et al. Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab. 2011;96:168-75.
54. Young KA, Engelman CD, Langefeld CD, et al. Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. J Clin Endocrinol Metab. 2009;94:3306-13.
55. Brown TT. Screening and Treating HIV-Infected Patients for Vitamin D Deficiency. Clinical Care Options. HIV Journal Options 2010;6.
56. Stanley TL, Grinspoon SK. GH/GHRH axis in HIV lipodystrophy. Pituitary. 2009;12:143-52.
57. Stanley TL, Joy T, Hadigan CM, et al. Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS 2009;23:1349-57.
58. Ferrer E, Rio LD, Martinez E, et al. Impact of Switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on Body Fat Redistribution in Virologically Suppressed HIV-Infected Adults. AIDS Res Hum Retroviruses 2011.
59. Kohli R, Shevitz A, Gorbach S, et al. A randomized placebocontrolled trial of metformin for the treatment of HIV lipodystrophy. HIV Med. 2007;8:420-6. (Pubitemid 47335264)
60. Mulligan K, Khatami H, Schwarz JM, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab. 2009;94:1137-44.
61. Bhasin S, Parker RA, Sattler F, et al. Effects of testosterone SUPPL.ementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity. J Clin Endocrinol Metab. 2007;92:1049-57. (Pubitemid 46465682)
62. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:239-52. (Pubitemid 38280649)
63. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007;45:286-97. (Pubitemid 47012375)
64. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIVand abdominal fat accumulation: a randomized controlled trial. JAMA. 2008;300:509-19.
65. Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292:210-8. (Pubitemid 38917998)
66. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, doseranging study of a growth hormone releasing factor in HIVinfected patients with abdominal fat accumulation. AIDS 2005;19:1279-87. (Pubitemid 41224897)
67. Lemieux S, Prud'homme D, Bouchard C, et al. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr. 1996;64:685-93. (Pubitemid 26398268)
68. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-70. (Pubitemid 350223390)
69. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53:311-22.
70. Falutz J, Mamputu JC, Potvin D, et al. Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in Human Immunodeficiency Virus-Infected Patients with Excess Abdominal Fat: A Pooled Analysis of Two Multicenter, Double-Blind Placebo-Controlled Phase 3 Trials with Safety Extension Data. J Clin Endocrinol Metab. 2010;95:4291-304.
71. Clayton PE, Banerjee I, Murray PG, et al. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol. 2011;7:11-24.
72. Popovic V, Mattsson AF, Gaillard RC, et al. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab. 2010;95:4449-54.
73. Theratechnologies Inc. Egrifta" (tesamorelin for injection): US prescribing information [online]. (Available from URL: http://www.accessata.fda. gov/drugsatfda-docs/label/2010/ 022505s0001b1. [Accessed 2011 Jun 2].)